Technical Analysis for ALXN - Alexion Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 126.07 -0.13% -0.16
ALXN closed down 0.13 percent on Friday, June 23, 2017, on 1.32 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ALXN trend table...

Date Alert Name Type % Chg
Jun 23 Upper Bollinger Band Walk Other 0.00%
Jun 22 Upper Bollinger Band Walk Other -0.13%
Jun 21 Upside 200 DMA Break Bullish 2.01%
Jun 21 Upper Bollinger Band Walk Other 2.01%
Jun 20 MACD Bullish Centerline Cross Bullish 5.90%

Older signals for ALXN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trails for its usage for the treatment of PNH pediatric trial, cold agglutinin disease, MPGN II/C3 nephropathy, hemolytic uremic syndrome, presensitized renal transplant, delayed kidney transplant graft function, ABO incompatible renal transplant, neuromyelitis optica, and myasthenia gravis. In addition, the company develops Asfotase alfa that is under Phase II clinical trail for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; and ALXN 1007, a novel humanized antibody for treating inflammatory disorders. Further, the company conducts preclinical trails on cPMP for treating metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Is ALXN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 145.41
52 Week Low 96.18
Average Volume 3,438,040
200-Day Moving Average 122.9509
50-Day Moving Average 115.6298
20-Day Moving Average 109.1685
10-Day Moving Average 117.593
Average True Range 4.0593
ADX 32.1
+DI 40.98
-DI: 14.76
Chandelier Exit (Long, 3 ATRs) 117.8421
Chandelier Exit (Short, 3 ATRs) 108.3579
Upper Bollinger Band 128.5622
Lower Bollinger Band 89.7748
Percent B (%b) 0.94
Bandwidth 0.355298
MACD Line 3.0912
MACD Signal Line 0.2667
MACD Histogram 2.8245